Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Assets Average (2016 - 2025)

Historic Assets Average for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to $240.5 million.

  • Heron Therapeutics' Assets Average rose 959.8% to $240.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 959.8%. This contributed to the annual value of $227.8 million for FY2024, which is 376.04% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Assets Average is $240.5 million, which was up 959.8% from $233.9 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Assets Average peaked at $378.3 million during Q3 2021, and registered a low of $211.1 million during Q2 2023.
  • Moreover, its 5-year median value for Assets Average was $235.9 million (2023), whereas its average is $260.4 million.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 3299.66% in 2021, then skyrocketed by 959.8% in 2025.
  • Heron Therapeutics' Assets Average (Quarter) stood at $329.0 million in 2021, then fell by 20.54% to $261.5 million in 2022, then decreased by 13.62% to $225.9 million in 2023, then rose by 0.49% to $227.0 million in 2024, then increased by 5.97% to $240.5 million in 2025.
  • Its Assets Average was $240.5 million in Q3 2025, compared to $233.9 million in Q2 2025 and $234.4 million in Q1 2025.